<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6013">
  <stage>Registered</stage>
  <submitdate>13/06/2016</submitdate>
  <approvaldate>13/06/2016</approvaldate>
  <nctid>NCT02826642</nctid>
  <trial_identification>
    <studytitle>A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia</studytitle>
    <scientifictitle>A Phase I, Open Label, Multicenter, Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CIDH305X2102</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Myeloid Leukemia (AML)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Acute leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Leukaemia - Chronic leukaemia</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Children's - Leukaemia &amp; Lymphoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IDH305

Experimental: Arm 1: Medically fit for induction - IDH305 + Standard of care for patients that are medically fit for induction.

Experimental: Arm 2 Medically unfit for induction - IDH305 + Standard of care for patients that are medically unfit for induction.


Treatment: drugs: IDH305


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Dose Limiting toxicities - (escalation only)</outcome>
      <timepoint>10 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Number of patients with adverse events (AEs)</outcome>
      <timepoint>36 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Area Under Curve (AUC) - To characterize the PK profile of IDH305 with SOC medications (each Arm)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Maximum Plasma Concentration (Cmax) - To characterize the PK profile of IDH305 with SOC medications (each Arm)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time taken to reach maximum plasma concentration (Tmax) - To characterize the PK profile of IDH305 with SOC medications (each Arm)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Complete remission rate (CRR) - To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall response rate (ORR) - To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Event free survival (EFS) - To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2)</outcome>
      <timepoint>36 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-- Previously untreated AML. Patients with untreated, high or very high risk MDS (according
        to rIPSS or equivalent) are also permitted in Arm 2.

          -  Documentation of IDH1R132 mutation of tumor

          -  ECOG performance status = 2

          -  Clinically fit for standard of care medication per protocol.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior treatment for AML or MDS

          -  Any severe or uncontrolled medical conditions that would prevent the patient's
             participation in the clinical study due to safety concerns or compliance with clinical
             study procedures such as the presence of other clinically significant cardiac,
             respiratory, gastrointestinal, renal, hepatic or neurological disease.

          -  Acute Promyelocytic Leukemia

          -  Women who are pregnant or lactating

        Other protocol-defined Inclusion/Exclusion may apply</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>88</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <anticipatedlastvisitdate>1/04/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Melbourne</hospital>
    <postcode>3000 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to evaluate the safety, tolerability and potential efficacy of
      IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia
      (AML).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02826642</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>